There was a time when Northwest Biotherapeutics (OTC:NWBO) emerged as one of the major gainers in the stock market due to its work on the DCVax-L, a product that is meant for treating the deadliest variants of cancer.
However, in recent times, the rally seems to have cooled off and the Northwest stock has been trading within a narrow range. The stock had hit the highest level of 52 weeks of $2.50 a share and eventually found a lower level at $1 level.
The next important trigger for the Northwest stock is going to be the top-line data that is going to be released following the Phase 3 trial f its cancer treatment product.
The keenness among investors with regards to the data from the DCVax-L trial is completely understandable. Moreover, it has also been indicated that the data from the Phase 3 trial could prove to be highly positive. In this situation, it could be a good idea to keep an eye on the Northwest stock.
Biotech, Tech, and Crypto reporter
Anthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.